Blog
RSS FeedPosted by Michael Wonder on 17 Jan 2018
NICE approves CDF funding for Janssen’s Darzalex
17 January 2018 - NICE is backing NHS use of Janssen’s Darzalex via the Cancer Drugs Fund for some adults ...
Posted by Michael Wonder on 17 Jan 2018
Consumers to be slugged with $200 private health insurance price rises
17 January 2018 - Consumers will be slugged with an average 4% rise in private health insurance premiums this year ...
Posted by Michael Wonder on 16 Jan 2018
How Ottawa's using a fake drug crisis to force through damaging pharmaceutical policy
16 January 2018 - There is no affordability crisis to justify expanding drug price regulation, or a new national government-run pharmacare ...
Posted by Michael Wonder on 16 Jan 2018
In a nutshell 2017: new issue with facts and graphics from the IQWiG
15 January 2018 - Third issue with focus on quality assurance/numerous graphs illustrate work results. ...
Posted by Michael Wonder on 16 Jan 2018
Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: studies of direct comparison are useful
4 January 2018 - Four dossier assessments involving comparisons between immunotherapies and chemotherapies for the same therapeutic indication in 2017/comparison ...
Posted by Michael Wonder on 16 Jan 2018
Private health insurers should improve 'useless' products, not punish people who avoid them: AMA
16 January 2018 - The Australian Medical Association says private health insurers should address low quality and sometimes "useless" products ...
Posted by Michael Wonder on 15 Jan 2018
Parents of kids with rare neuromuscular disorder want funding for expensive drug
15 January 2018 - Parents whose children are battling a genetic disease called spinal muscular atrophy are calling on the ...
Posted by Michael Wonder on 15 Jan 2018
German watchdog calls for direct comparison of cancer immunotherapies
16 January 2018 - Germany’s drug assessment body has criticized a lack of data directly comparing drugs in a promising ...
Posted by Michael Wonder on 15 Jan 2018
Scottish Medicines Consortium rejects cancer drugs for routine use on NHS
15 January 2018 - Drugs used to treat two rare cancers have been turned down for routine use by the ...
Posted by Michael Wonder on 15 Jan 2018
SMC - January 2018 decisions
15 January 2018 - SMC publishes advice on four new medicines. ...
Posted by Michael Wonder on 15 Jan 2018
PHARMAC approves funding for treatment for 'mighty Mon'
14 January 2018 - A woman fighting cancer for the third time - and who was told she may only ...
Posted by Michael Wonder on 14 Jan 2018
Agenda for 10 January TC meeting
10 January 2018 - HAS has posted the agenda for the next scheduled TC meeting. ...
Posted by Michael Wonder on 14 Jan 2018
A managed access approach to appraising new cancer drugs in England
12 January 2018 - The changing regulatory landscape brings new challenges to health technology assessment. Marketing authorisations are being granted as ...
Posted by Michael Wonder on 13 Jan 2018
Estimating the reference incremental cost-effectiveness ratio for the Australian health system
22 December 2017 - The objective of this study was to estimate the expected incremental cost per quality-adjusted life-year (QALY) ...
Posted by Michael Wonder on 13 Jan 2018
Price disclosure 2018 April cycle outcomes summary
12 January 2018 - The summary of price disclosure price reductions for the 2018 April Cycle (fourth remove originator cycle) has ...